Candriam S.C.A. decreased its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 4.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 227,476 shares of the company's stock after selling 11,524 shares during the quarter. Candriam S.C.A. owned 0.36% of MoonLake Immunotherapeutics worth $12,318,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of MLTX. GSA Capital Partners LLP increased its holdings in shares of MoonLake Immunotherapeutics by 1.9% in the 3rd quarter. GSA Capital Partners LLP now owns 22,127 shares of the company's stock worth $1,116,000 after buying an additional 403 shares during the last quarter. US Bancorp DE purchased a new position in shares of MoonLake Immunotherapeutics during the 3rd quarter valued at about $44,000. HighVista Strategies LLC lifted its position in MoonLake Immunotherapeutics by 3.1% in the 3rd quarter. HighVista Strategies LLC now owns 43,541 shares of the company's stock worth $2,195,000 after buying an additional 1,292 shares during the last quarter. Parkman Healthcare Partners LLC boosted its stake in MoonLake Immunotherapeutics by 1.6% in the third quarter. Parkman Healthcare Partners LLC now owns 102,813 shares of the company's stock worth $5,184,000 after buying an additional 1,589 shares in the last quarter. Finally, Harbor Capital Advisors Inc. grew its position in MoonLake Immunotherapeutics by 2.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 79,648 shares of the company's stock valued at $4,313,000 after acquiring an additional 2,180 shares during the last quarter. Hedge funds and other institutional investors own 93.85% of the company's stock.
A number of brokerages recently commented on MLTX. Needham & Company LLC lifted their target price on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. HC Wainwright restated a "buy" rating and set a $100.00 target price on shares of MoonLake Immunotherapeutics in a report on Thursday, February 27th. Finally, The Goldman Sachs Group decreased their price target on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating on the stock in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, MoonLake Immunotherapeutics currently has an average rating of "Buy" and an average price target of $83.20.
Get Our Latest Research Report on MoonLake Immunotherapeutics
MLTX stock traded down $1.79 during midday trading on Friday, hitting $38.03. The company's stock had a trading volume of 310,495 shares, compared to its average volume of 340,612. The firm has a market capitalization of $2.43 billion, a price-to-earnings ratio of -29.48 and a beta of 1.31. The company has a 50 day moving average of $45.10 and a two-hundred day moving average of $48.64. MoonLake Immunotherapeutics has a 12 month low of $37.55 and a 12 month high of $58.26.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.09). On average, analysts anticipate that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current fiscal year.
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.